The final participant has completed the last visit as part of EFZO-FIT, a Phase 3 clinical trial testing Atyr Pharma’s experimental treatment efzofitimod, in adults with pulmonary sarcoidosis. Top-line results are expected in the coming months. “Completing this first-ever global Phase 3 and largest interventional study conducted for patients…
News
The Foundation for Sarcoidosis Research (FSR) has awarded $450,000 to three scientists to support research projects related to sarcoidosis diagnosis, treatment, and care. This funding comes through FSR’s Early Career Fellowship Grant, which is designed to provide scientists early in their career with resources for advancing sarcoidosis research.
Sinonasal sarcoidosis, when the disease affects the nasal cavity and the surrounding air-filled cavities called the sinuses, mainly affects women and manifests as nasal obstruction, according to a review study. More than half of people with sinonasal sarcoidosis experience symptom lessening after treatment with medications and/or surgery. “Prompt…
The Foundation for Sarcoidosis Research (FSR) has launched an enhanced version of its patient registry, FSR-SARC, to help maximize the impact of patient participation in research. “Now in its tenth year, the Registry has been one of our most powerful tools to elevate patient voices in the advancement of…
A new study from researchers in Turkey suggests that a ratio taking into account the amount of angiotensin-converting enzyme (ACE) and of lymphocytes, a type of white blood cell — a ratio elevated in patients with recurrent disease after stopping treatment — is a potential biomarker for people with…
Most people with inflammatory conditions reported overall satisfaction, convenience, and confidence when self-administering Acthar Gel (repository corticotropin injection) through a single-dose, prefilled injector called SelfJect. That’s according to a survey-based study sponsored by the therapy’s developer, Mallinckrodt. The study involved 54 patients living in the U.S., eight of…
A Partner Grant from the Foundation for Sarcoidosis Research (FSR) and the American Thoracic Society (ATS) will support a research project focused on possible connections between air pollution and outcomes of people with sarcoidosis. The grant, totaling $100,000 over two years, was awarded to Mark Mallozzi, MD,…
The first participants in a Phase 2 clinical trial testing brepocitinib, Roivant’s experimental oral treatment, in adults with cutaneous sarcoidosis have been dosed, and top-line results are expected in the second half of 2026. The company had this year announced plans to launch this proof-of-concept trial, called BEACON…
Methotrexate appears to take longer to start acting, but is no less effective than the corticosteroid prednisone as a first-line treatment for pulmonary sarcoidosis, according to the early findings of an ongoing Phase 4 clinical trial. The researchers noted that, while methotrexate treatment is associated with a similar number…
Many people with moderate or severe pulmonary sarcoidosis — the target market for the investigational therapy efzofitimod — are highly burdened by the disease and are dependent on corticosteroids that can have serious side effects, according to real-world analyses. “New real-world evidence underscores the growing burden of patients…
Recent Posts
- New report highlights unmet needs and treatment burdens in sarcoidosis
- Cardiac sarcoidosis symptoms at diagnosis help predict long-term risk
- Methotrexate is safer second-line sarcoidosis treatment than MMF
- A holiday gift guide for your loved one with sarcoidosis
- FSR gathers global leaders to drive progress in sarcoidosis research
- New genetic clues connect sarcoidosis with lung cancer risk
- When patients and caregivers swap roles, empathy usually follows
- Underdiagnosis of cardiac sarcoidosis leaves people at risk
- Repurposing drugs may improve survival for people with sarcoidosis
- Few with sarcoidosis see lung specialist within a year of diagnosis